Six months into a campaign to rout out corruption from the Chinese healthcare industry, many of the underlying issues in the sector remain unchanged.
Last summer, China’s ongoing corruption crackdown found a new target: the healthcare sector.
In an effort to lower medical costs at a time of slowing economic growth, the Chinese government targeted unscrupulous doctors, hospital officials, and pharmaceutical executives.
By mid-August, more than 170 hospital administrators were under investigation, according to state media, a dozen Chinese healthcare companies had withdrawn IPO plans, and $142 billion worth of value in Chinese heal
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
What is so hard about making chips in America? And can the U.S. do anything about it? As part of his series, 'Remaking the Chain,' Luke Patey went searching for answers from America's past and from the last country to threaten its mantle as the world’s leading economy.
The political scientist and sinologist talks about the early days of the pandemic in Wuhan, and how the Chinese authorities’ lack of transparency led the virus to spread rapidly.
Navigate China's Business Landscape with Confidence.